Clearside Biomedical's (CLSD) Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting Oct 22, 2024 07:05AM
Clearside Biomedical’s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting Oct 22, 2024 07:05AM
Clearside Biomedical (CLSD) Reports Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX Oct 9, 2024 06:30AM
Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes Oct 9, 2024 06:30AM
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD Aug 27, 2024 07:05AM


Dec 14, 2023 07:05AM Clearside Biomedical (CLSD) Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Dec 14, 2023 07:05AM Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Nov 1, 2023 07:05AM Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
Oct 16, 2023 07:05AM Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting
Jul 17, 2023 07:05AM Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
Jun 1, 2023 07:05AM Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD